Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$29.98
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.24M
Market Cap
HK$35.58B
Enterprise ValueHK$8.84K
Total Cash (Recent Filing)HK$4.23B
Total Debt (Recent Filing)HK$82.43M
Price to Earnings (P/E)32.4
Beta1.45
Next Earnings
Nov 04, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield0.61%
Share Statistics
EPS (TTM)1.33
Shares Outstanding118,995,210
10 Day Avg. Volume3,889,696
30 Day Avg. Volume6,239,525
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside8.90% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.17
Revenue Forecast (FY)HK$2.25B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage And Strong Capital BaseExtremely low leverage reduces refinancing risk and interest burden, while a substantial equity base gives JOINN flexibility to fund laboratories, maintain capacity, and withstand fluctuations in CRO project demand.
TTM Revenue And Earnings RecoveryThe TTM recovery indicates that customer demand and project activity can rebound after weaker periods. Positive profitability and EPS improvement provide a stronger base for funding operations and supporting future research-service expansion.
Positive Operating Cash GenerationPositive cash generation means the fee-for-service model is converting research activity into funding for operations and reinvestment. This reduces reliance on external financing, particularly alongside the company’s very low leverage.
Bears Say
Multi-year Revenue ContractionA sustained decline across the annual revenue base signals inconsistent project wins, customer spending, or capacity utilization. The recent rebound is encouraging, but the broader contraction weakens confidence in durable growth visibility.
Significant Gross Margin CompressionLower gross margins may reflect weaker pricing power, a less favorable study mix, or rising laboratory and operating costs. If persistent, compression limits profit scalability even when CRO project volumes recover.
Volatile And Recently Weaker Free Cash FlowUnstable cash conversion makes internally funded expansion less predictable and may reflect working-capital swings or elevated reinvestment needs. The recent drawdown reduces confidence in the consistency of cash returns.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$29.98 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$35.58B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 59 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported HK$0.793 earnings per share for the quarter, beating the consensus estimate of HK$0.556 by HK$0.237.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Undervalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.61%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.793 in its last earnings report, beating expectations of HK$0.556. Following the earnings report the stock price went down -2.014%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.56%
12-Months-Change
Fundamentals
Return on Equity
0.61%
Trailing 12-Months
Asset Growth
20.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$23.00
▲(8.90% Upside)
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―